{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T18:58:16Z","timestamp":1785351496469,"version":"3.55.0"},"reference-count":27,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T00:00:00Z","timestamp":1785024000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Workplace Health Saf"],"abstract":"<jats:p>Post-exposure prophylaxis (PEP) with antiretroviral therapy is highly effective in preventing human immunodeficiency virus transmission but can be complicated by hypersensitivity reactions, particularly when sequential regimen substitution is required due to adverse events. We describe the case of a 58-year-old female physician who developed an acute vulvovaginal hypersensitivity reaction within one hour of initiating bictegravir\/emtricitabine\/tenofovir alafenamide for occupational PEP, followed by drug-induced hypersensitivity syndrome after substitution with darunavir. The patient completed her prophylactic course and did not seroconvert to human immunodeficiency virus or hepatitis B virus. This progression illustrates two novel points: (1) vulvovaginal mucosal hypersensitivity as an underrecognized phenotype of bictegravir\/emtricitabine\/tenofovir alafenamide toxicity, and (2) heightened risk of severe reactions with sequential prescribing in patients with prior sulfonamide allergy. The case highlights the value of allergy risk stratification in urgent PEP protocols and underscores an opportunity to strengthen sex-specific safety reporting in antiretroviral research. Integrating these considerations into occupational health practice may help prevent life-threatening adverse events, reduce time away from work, and support healthcare worker well-being and productivity.<\/jats:p>","DOI":"10.1177\/21650799261470385","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T05:25:01Z","timestamp":1785129901000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Workplace Safety Considerations in Post-Exposure HIV Prophylaxis: A Case Report of Atypical Hypersensitivity in a Healthcare Worker"],"prefix":"10.1177","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6702-1664","authenticated-orcid":false,"given":"Riya","family":"Goel","sequence":"first","affiliation":[{"name":"Emory University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura Delong","family":"Aspey","sequence":"additional","affiliation":[{"name":"Emory University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghiara Alexandra","family":"Lugo-Diaz","sequence":"additional","affiliation":[{"name":"University of Texas Health"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6900-9893","authenticated-orcid":false,"given":"Nadi Nina","family":"Kaonga","sequence":"additional","affiliation":[{"name":"Emory University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Flowers","sequence":"additional","affiliation":[{"name":"Emory University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,7,26]]},"reference":[{"key":"e_1_3_2_2_1","doi-asserted-by":"crossref","unstructured":"Auerbach J. D. Malone S. Forsyth A. D. (2024). Occupational post-exposure prophylaxis among healthcare workers: A scoping review of factors affecting optimal utilization. Journal of the International AIDS Society 27(8) Article e26341. https:\/\/doi.org\/10.1002\/jia2.26341","DOI":"10.1002\/jia2.26341"},{"key":"e_1_3_2_3_1","doi-asserted-by":"crossref","unstructured":"Bhatt K. P. Alsoud F. Prashad A. Ortega-Tola J. Singh V. R. Patel P. Michel G. (2023). Drug reaction with eosinophilia and systemic symptoms (DRESS): An unusual manifestation of multi-visceral abnormalities and long-term outcome. Discoveries 11(3) Article e170. https:\/\/doi.org\/10.15190\/d.2023.9","DOI":"10.15190\/d.2023.9"},{"key":"e_1_3_2_4_1","doi-asserted-by":"crossref","unstructured":"Buijs B. S. van den Berk G. E. Boateng C. P. Hoepelman A. I. van Maarseveen E. M. Arends J. E. (2015). Cross-reactivity between darunavir and trimethoprim-sulfamethoxazole in HIV-infected patients. AIDS 29(7) 785\u2013791. https:\/\/doi.org\/10.1097\/QAD.0000000000000612","DOI":"10.1097\/QAD.0000000000000612"},{"key":"e_1_3_2_5_1","doi-asserted-by":"crossref","unstructured":"Cardo D. M. Culver D. H. Ciesielski C. A. Srivastava P. U. Marcus R. Abiteboul D. Heptonstall J. Ippolito G. Lot F. McKibben P. S. Bell D. M. (1997). A case-control study of HIV seroconversion in health care workers after percutaneous exposure. Centers for Disease Control and Prevention Needlestick Surveillance Group. The New England Journal of Medicine 337(21) 1485\u20131490. https:\/\/doi.org\/10.1056\/NEJM199711203372101","DOI":"10.1056\/NEJM199711203372101"},{"key":"e_1_3_2_6_1","unstructured":"Centers for Disease Control and Prevention. (2025 February 10). Clinical Guidance for PEP. HIV Nexus: CDC Resources for Clinicians. https:\/\/www.cdc.gov\/hivnexus\/hcp\/pep\/index.html"},{"key":"e_1_3_2_7_1","doi-asserted-by":"crossref","unstructured":"DenAdel M. A. Hendrickson S. E. Fuchs E. (2022). Stevens-Johnson syndrome: Past present and future directions gynecologic manifestations and management in SJS\/TEN. Frontiers in Medicine 9 Article 874445. https:\/\/doi.org\/10.3389\/fmed.2022.874445","DOI":"10.3389\/fmed.2022.874445"},{"key":"e_1_3_2_8_1","doi-asserted-by":"crossref","unstructured":"De Oliveira J. C. Alves M. R. Lopes L. P. N. Motter F. R. Iwami R. S. Bergamaschi C. de C. Silva M. T. Scalco D. L. Lucio D. de S. Mazzei L. G. Derech R. D. Itria A. Barreto J. O. M. Lopes L. C. (2024). Rates of adverse events of antiretroviral therapy in women living with HIV\/AIDS: A systematic review and meta-analysis. BMJ Open 14(7) Article e079292. https:\/\/doi.org\/10.1136\/bmjopen-2023-079292","DOI":"10.1136\/bmjopen-2023-079292"},{"key":"e_1_3_2_9_1","doi-asserted-by":"crossref","unstructured":"Dreischulte T. Shahid F. Muth C. Schmiedl S. Emil Haefeli W. (2022). Prescribing cascades: How to detect them prevent them and use them appropriately. Deutsches \u00c4rzteblatt International 119(44) 745\u2013752. https:\/\/doi.org\/10.3238\/arztebl.m2022.0306","DOI":"10.3238\/arztebl.m2022.0306"},{"issue":"4","key":"e_1_3_2_10_1","first-page":"575","article-title":"Drug-induced hypersensitivity syndrome after initiation of darunavir and raltegravir","volume":"50","author":"Eyer-Silva W. D. A.","year":"2016","unstructured":"Eyer-Silva W. D. A., Freire M. A. L., Silva G. A. R. D. (2016). Drug-induced hypersensitivity syndrome after initiation of darunavir and raltegravir. Images in Infectious Diseases, 50(4), 575\u2013576.","journal-title":"Images in Infectious Diseases"},{"key":"e_1_3_2_11_1","doi-asserted-by":"crossref","unstructured":"Gulick R. M. Mellors J. W. Havlir D. Eron J. J. Gonzalez C. McMahon D. Jonas L. Meibohm A. Holder D. Schleif W. A. Condra J. H. Emini E. A. Isaacs R. Chodakewitz J. A. Richman D. D. (1998). Simultaneous vs sequential initiation of therapy with indinavir zidovudine and lamivudine for HIV-1 infection: 100-week follow-up. JAMA 280(1) 35\u201341. https:\/\/doi.org\/10.1001\/jama.280.1.35","DOI":"10.1001\/jama.280.1.35"},{"key":"e_1_3_2_12_1","doi-asserted-by":"crossref","unstructured":"Hama N. Abe R. Gibson A. Phillips E. J. (2022). Drug-induced hypersensitivity syndrome (DIHS)\/drug reaction with eosinophilia and systemic symptoms (DRESS): Clinical features and pathogenesis. The Journal of Allergy and Clinical Immunology. In Practice 10(5) 1155\u20131167.e5. https:\/\/doi.org\/10.1016\/j.jaip.2022.02.004","DOI":"10.1016\/j.jaip.2022.02.004"},{"key":"e_1_3_2_13_1","unstructured":"International Committee of Medical Journal Editors (ICMJE). (2026). Recommendations. https:\/\/www.icmje.org\/recommendations\/"},{"key":"e_1_3_2_14_1","doi-asserted-by":"crossref","unstructured":"Liu S. Yuan D. Zhou Y. Fu G. Wang B. (2023). Adherence adverse drug reactions and discontinuation associated with adverse drug reactions of HIV post-exposure prophylaxis: A meta-analysis based on cohort studies. Annals of Medicine 55(2) Article 2288309. https:\/\/doi.org\/10.1080\/07853890.2023.2288309","DOI":"10.1080\/07853890.2023.2288309"},{"key":"e_1_3_2_15_1","doi-asserted-by":"crossref","unstructured":"Naranjo C. A. Busto U. Sellers E. M. Sandor P. Ruiz I. Roberts E. A. Janecek E. Domecq C. Greenblatt D. J. (1981). A method for estimating the probability of adverse drug reactions. Clinical Pharmacology and Therapeutics 30(2) 239\u2013245. https:\/\/doi.org\/10.1038\/clpt.1981.154","DOI":"10.1038\/clpt.1981.154"},{"key":"e_1_3_2_16_1","unstructured":"National Library of Medicine. (2025). DailyMed\u2014DARUNAVIR- darunavir tablet film coated. https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=49606d5e-f45f-45eb-9ab8-15aa6a233875"},{"key":"e_1_3_2_17_1","unstructured":"National Library of Medicine. (2026). DailyMed\u2014BIKTARVY-bictegravir sodium emtricitabine and tenofovir alafenamide fumarate tablet. https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=664cb8f0-1f65-441b-b0d9-ba3d798be309#S14.3"},{"key":"e_1_3_2_18_1","unstructured":"Oakley A. M. Krishnamurthy K. (2025). Stevens-Johnson syndrome. StatPearls Publishing. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK459323\/"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200312010-00008"},{"key":"e_1_3_2_20_1","doi-asserted-by":"crossref","unstructured":"Palella F. J. Delaney K. M. Moorman A. C. Loveless M. O. Fuhrer J. Satten G. A. Aschman D. J. Holmberg S. D. (1998). Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. The New England Journal of Medicine 338(13) 853\u2013860. https:\/\/doi.org\/10.1056\/NEJM199803263381301","DOI":"10.1056\/NEJM199803263381301"},{"key":"e_1_3_2_21_1","doi-asserted-by":"crossref","unstructured":"Peter J. Choshi P. Lehloenya R. J. (2019). Drug hypersensitivity in HIV infection. Current Opinion in Allergy and Clinical Immunology 19(4) 272\u2013282. https:\/\/doi.org\/10.1097\/ACI.0000000000000545","DOI":"10.1097\/ACI.0000000000000545"},{"issue":"7","key":"e_1_3_2_22_1","first-page":"354","article-title":"Severe gynecologic sequelae of Stevens-Johnson syndrome and toxic epidermal necrolysis caused by ibuprofen: A case report","volume":"58","author":"Pliskow S.","year":"2013","unstructured":"Pliskow S. (2013). Severe gynecologic sequelae of Stevens-Johnson syndrome and toxic epidermal necrolysis caused by ibuprofen: A case report. The Journal of Reproductive Medicine, 58(7\u20138), 354\u2013356.","journal-title":"The Journal of Reproductive Medicine"},{"key":"e_1_3_2_23_1","doi-asserted-by":"crossref","unstructured":"Ramirez G. A. Ripa M. Burastero S. Benanti G. Bagnasco D. Nannipieri S. Monardo R. Ponta G. Asperti C. Cilona M. B. Castagna A. Dagna L. Yacoub M.-R. (2023). Drug reaction with eosinophilia and systemic symptoms (DRESS): Focus on the pathophysiological and diagnostic role of viruses. Microorganisms 11(2) Article 346. https:\/\/doi.org\/10.3390\/microorganisms11020346","DOI":"10.3390\/microorganisms11020346"},{"key":"e_1_3_2_24_1","unstructured":"Spach D. Kalapila A. (2025). Core concepts\u2014Occupational postexposure prophylaxis\u2014Prevention of HIV. National HIV Curriculum. https:\/\/www.hiv.uw.edu\/go\/prevention\/occupational-postexposure-prophylaxis\/core-concept\/all"},{"key":"e_1_3_2_25_1","doi-asserted-by":"crossref","unstructured":"Squillace N. Ricci E. Maggi P. Taramasso L. Menzaghi B. De Socio G. V. Piconi S. Maurizio Celesia B. Orofino G. Sarchi E. Pellican\u00f2 G. F. Simeone F. Valsecchi L. Bandera A. Cenderello G. Attala L. Angioni G. Falasca K. Cascio A. . . . CISAI Study Group. (2023). Real-life safety of emtricitabine\/tenofovir alafenamide\/bictegravir. PLoS ONE 18(8) Article e0289132. https:\/\/doi.org\/10.1371\/journal.pone.0289132","DOI":"10.1371\/journal.pone.0289132"},{"key":"e_1_3_2_26_1","doi-asserted-by":"crossref","unstructured":"Tanner M. R. (2025). Antiretroviral postexposure prophylaxis after sexual injection drug use or other nonoccupational exposure to HIV\u2014CDC recommendations United States 2025. MMWR 74(1) 1\u201356. https:\/\/doi.org\/10.15585\/mmwr.rr7401a1","DOI":"10.15585\/mmwr.rr7401a1"},{"key":"e_1_3_2_27_1","doi-asserted-by":"crossref","unstructured":"Warren K. J. Boxwell D. E. Kim N. Y. Drolet B. A. (1998). Nevirapine-associated Stevens-Johnson syndrome. The Lancet 351(9102) Article 567. https:\/\/doi.org\/10.1016\/S0140-6736(98)24008-6","DOI":"10.1016\/S0140-6736(98)24008-6"},{"key":"e_1_3_2_28_1","doi-asserted-by":"crossref","unstructured":"Wolf R. Matz H. Marcos B. Orion E. (2005). Drug rash with eosinophilia and systemic symptoms vs toxic epidermal necrolysis: The dilemma of classification. Clinics in Dermatology 23(3) 311\u2013314. https:\/\/doi.org\/10.1016\/j.clindermatol.2005.02.001","DOI":"10.1016\/j.clindermatol.2005.02.001"}],"container-title":["Workplace Health &amp; Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/21650799261470385","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/21650799261470385","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/21650799261470385","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T18:00:23Z","timestamp":1785348023000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/21650799261470385"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,26]]},"references-count":27,"alternative-id":["10.1177\/21650799261470385"],"URL":"https:\/\/doi.org\/10.1177\/21650799261470385","relation":{},"ISSN":["2165-0799","2165-0969"],"issn-type":[{"value":"2165-0799","type":"print"},{"value":"2165-0969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,26]]},"article-number":"21650799261470385"}}